SEROLOGIC MARKERS OF HTLV-I/II INFECTION

我们正在生产一组HTLV-II血统血清/血浆试剂， 用于评估检测试剂盒性能的研究小组。 小组 正在使用捐赠的标本和购买的标本进行组装， 标本 通过以下方法确定标本中含有抗体： 某些许可或实验测试的反应性。 的存在 使用蛋白质印迹和RIPA的组合确认抗体。细胞 使用PCR确定个体被感染。将样品 通过分型方法（包括使用分型试验）确定为HTLV-II 试剂盒和PCR。 我们正在评估此面板在许可的 HTLV-I测试以及正在审查的测试。 初步结果使用此 3月，FDA血液制品咨询委员会提交了一份小组报告， 1993. 我们的研究结果表明，许可的HTLV-I的能力范围很广， 检测HTLV-II标本的试验。 我们继续收集血统 HTLV-II试剂。

We are generating a panel of HTLV-II pedigreed serum/plasma reagents as a research panel to be used to evaluate performance of test kits. The panel is being assembled using both contributed specimens as well as purchased specimens. The specimens were determined to contain antibodies by reactivity on certain licensed or experimental tests. The presence of antibody was confirmed using a combination of western blot and RIPA. Cells from individuals were determined to be infected using PCR. The samples were determined to be HTLV-II by typing methods including the use of typing test kits and PCR. We are evaluating the performance of this panel on licensed HTLV-I tests as well as tests under review. Preliminary results using this panel were presented to the FDA Blood Products Advisory Committee in March 1993. Our results indicated a wide range in the ability of licensed HTLV-I tests to detect HTLV-II specimens. We are continuing to assemble pedigreed HTLV-II reagents.